DNA antibody constructs and method of using same

An antibody and antigen technology, applied in the field of DNA antibody constructs and its use, can solve the problems of not being optimal and short-term stability of antibody preparations, etc.

Pending Publication Date: 2019-06-14
大卫 B 韦纳 +6
View PDF49 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, the long-term stability of these antibody formulations is often short-lived and suboptimal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0444] Rapid and long-term immunity against chikungunya virus elicited by DNA-encoded antibody prophylaxis and DNA vaccination

[0445] Vaccination is known to exhibit a lag phase before immunity is produced; thus, during infection, there is a time gap before the immune response becomes effective. Specific new approaches are provided below that exploit the benefits of vaccines and innate immune responses and the rapid generation of effective immunity using DNA synthetic antibodies or dMabs.

[0446] Antibody-based prophylaxis / therapy requiring electroporation-mediated delivery of a synthetic plasmid encoding a bioactive anti-chikungunya virus envelope mAb (designated dMAb) was designed and evaluated against the virus through a novel passive immunization-based strategy Efficacy and ability to overcome shortcomings inherent in conventional active vaccination. A single intramuscular injection of CHIKV-dMAb produced antibodies in vivo faster than active vaccination with CHIKV-DNA...

Embodiment 2

[0487] Example 2: Rapid and long-term immunity against Zika virus elicited by DNA-encoded antibody prophylaxis and DNA vaccination

[0488] Vaccination is known to exhibit a lag phase before immunity is produced; thus, during infection, there is a time gap before the immune response becomes effective. Specific new approaches are provided below that exploit the benefits of vaccines and innate immune responses and the rapid generation of effective immunity using DNA synthetic antibodies or dMabs.

[0489] Through a novel passive immunization-based strategy, antibody-based prophylaxis / therapy requiring electroporation-mediated delivery of a synthetic plasmid encoding a bioactive anti-Zika virus envelope mAb (designated dMAb) was designed and evaluated for antiviral efficacy and The ability to overcome the shortcomings inherent in conventional active vaccination. A single intramuscular injection of ZIKV-dMAb produced antibodies in vivo faster than active vaccination with ZIKV-DNA...

Embodiment 3

[0522] Example 3: Rapid and long-term immunity against Ebola virus elicited by DNA-encoded antibody prophylaxis and DNA vaccination

[0523] Vaccination is known to exhibit a lag phase before immunity is produced; thus, during infection, there is a time gap before the immune response becomes effective. Specific new approaches are provided below that exploit the benefits of vaccines and innate immune responses and the rapid generation of effective immunity using DNA synthetic antibodies or dMabs.

[0524] Antibody-based prophylaxis / therapy requiring electroporation-mediated delivery of a synthetic plasmid encoding a bioactive anti-Ebola virus envelope mAb (designated dMAb) was designed and evaluated for antiviral efficacy through a novel passive immunization-based strategy And the ability to overcome the shortcomings inherent in conventional active vaccination. A single intramuscular injection of EBOV-dMAb produced antibodies in vivo faster than active vaccination with EBOV-DN...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

Disclosed herein is a composition comprising the combination of a nucleic acid sequence encoding a desired polypeptide that elicits an immune response in a mammal and a nucleic acid sequence encodingan antibody, a fragment thereof, a variant thereof, or a combination thereof.

Description

[0001] Citations to related applications [0002] This application claims U.S. Provisional Application No. 62 / 311,316, filed March 21, 2016, U.S. Provisional Application No. 62 / 396,748, filed September 19, 2016, U.S. Provisional Application No. 62 / 396,750, filed September 19, 2016 , U.S. Provisional Application No. 62 / 417,093, filed November 3, 2016, U.S. Provisional Application No. 62 / 332,381, filed May 4, 2016, U.S. Provisional Application No. 62 / 376,162, filed August 17, 2016, 2016 Priority to U.S. Provisional Application No. 62 / 429,454, filed December 2, 2016, and U.S. Provisional Application No. 62 / 429,473, filed December 2, 2016, each of which is hereby incorporated by reference Incorporated as a whole. technical field [0003] The present invention relates to DNA vaccines in combination with compositions comprising recombinant nucleic acid sequences for the in vivo production of one or more synthetic antibodies and functional fragments thereof. The compositions of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00C12N9/48C12N9/64
CPCA61K2039/545A61K2039/55516C12N2770/24134C12N2770/36134A61K39/12A61P31/12Y02A50/30A61K39/42C07K14/005C07K16/1081A61K2039/53C07K2319/01C07K2317/50C07K2319/50A61K2039/505A61K2039/575C07K2317/76
Inventor 大卫·B·韦纳卡鲁皮亚·穆苏马尼塞利克·夫林盖尼兰詹·萨尔德赛萨拉·埃利奥特严健阿米·帕特尔
Owner 大卫 B 韦纳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap